Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Biotech Services HoldingsHKSE:08037 -1.54%19 Days Inventory is 122.37 as of Dec. 2025, which is 270% above its 10-year median of 33.04. GuruFocus rates HKSE:08037 with a GF Score™ of 19/100 and a GF Value™ of HK$0.27 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 179 Medical Diagnostics & Research companies, China Biotech Services Holdings ranks worse than 56.42% on this metric.
The historical rank and industry rank for China Biotech Services Holdings's Days Inventory or its related term are showing as below:
HKSE:08037'
s Days Inventory Range Over the Past 10 Years
Min: 5.16 Med: 33.04 Max: 113.51
Current: 80.39
During the past 13 years, China Biotech Services Holdings's highest Days Inventory was 113.51. The lowest was 5.16. And the median was 33.04.
HKSE:08037's Days Inventory is ranked worse than 56.42% of 179
companies
in the Medical Diagnostics & Research industry
Industry Median: 65.04
vs HKSE:08037: 80.39
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
China Biotech Services Holdings's Inventory Turnover for the
six
months ended in Dec. 2025 was 1.49.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
China Biotech Services Holdings's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.57.
China Biotech Services Holdings (HKSE:08037) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
China Biotech Services Holdings's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
China Biotech Services Holdings's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
China Biotech Services Holdings Days Inventory Related Terms
China Biotech Services Holdings Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Biotech Services Holdings Days Inventory Chart
HKSE:08037 vs TMO, DHR, IDXX: Days Inventory Comparison
For the Diagnostics & Research subindustry, China Biotech Services Holdings's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Biotech Services Holdings Days Inventory vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, China Biotech Services Holdings's Days Inventory distribution charts can be found below:
* The bar in red indicates where China Biotech Services Holdings's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Biotech Services Holdings (HKSE:08037) has a Days Inventory of 122.37 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on China Biotech Services Holdings and its competitors. This is 270% above median its historical median of 33.04. Over the past decade, China Biotech Services Holdings' Days Inventory has ranged from 5.16 to 113.51. According to the industry distribution chart, China Biotech Services Holdings ranks #101 out of 179 companies in the Medical Diagnostics & Research industry, placing it in the top 56.4%.
Is China Biotech Services Holdings' Days Inventory too high?
China Biotech Services Holdings' current Days Inventory of 122.37 is 270% above median its 10-year median of 33.04. Over the past 10 years, this metric has ranged from a low of 5.16 to a high of 113.51. The Medical Diagnostics & Research industry median Days Inventory is 65.04. China Biotech Services Holdings' value of 122.37 is 88.1% above this industry median. Based on the distribution chart, China Biotech Services Holdings ranks #101 out of 179 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, China Biotech Services Holdings has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Biotech Services Holdings' Days Inventory compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, China Biotech Services Holdings ranks #101 out of 179 companies for Days Inventory. This places China Biotech Services Holdings in the lower half of its industry. The industry median Days Inventory is 65.04. China Biotech Services Holdings' value of 122.37 is 88.1% above this benchmark. Historically, China Biotech Services Holdings' own Days Inventory has ranged from 5.16 to 113.51 over the past decade. While the company's 10-year median is 33.04 vs. the industry median of 65.04, China Biotech Services Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Diagnostics & Research company?
The median Days Inventory among Medical Diagnostics & Research companies is 65.04, based on 179 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Biotech Services Holdings's current Days Inventory of 122.37 is 88.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on China Biotech Services Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Days Inventory is 65.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Biotech Services Holdings's current Days Inventory is 122.37, which is 270% above median its own 10-year median of 33.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Biotech Services Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Biotech Services Holdings (HKSE:08037) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.27, compared to a current price of HK$0.64 — trading 137% above its estimated fair value. The current Days Inventory is 122.37, which is 270% above median its 10-year median of 33.04 and 88.1% above the Medical Diagnostics & Research industry median of 65.04. China Biotech Services Holdings' overall GF Score™ is 19/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For China Biotech Services Holdings (HKSE:08037), the current Days Inventory is 122.37 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Biotech Services Holdings (HKSE:08037) Overvalued in 2026?
Based on GuruFocus' analysis, China Biotech Services Holdings stock appears to be overvalued.
The current stock price of HK$0.64 is trading 137% above its estimated GF Value™ of HK$0.27.
GuruFocus considers China Biotech Services Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:08037:
Days Inventory: 122.37 (270% above median its 10-year median of 33.04)
GF Value™: HK$0.27 vs. price of HK$0.64 (137% above fair value)
Industry Position: 88.1% above the Medical Diagnostics & Research median (#101 of 179)
No single metric tells the full story. See the HKSE:08037 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Biotech Services Holdings Business Description
China Biotech Services Holdings Ltd is an investment holding company. It operates through five segments: Pharmaceutical Products, Medical and Health-Related Services, Immunotherapy, Insurance brokerage, BNCT, and Others. It derives prime revenue from the Medical & health-related services segment, which involves the provision of medical laboratory testing & health check services. The group has a business presence in Hong Kong & the PRC, of which key revenue is generated from Hong Kong. Immunotherapy-provision of tumor immune cell therapy & health management services. Pharmaceutical products-sale & distribution of health-related & pharmaceutical products. Insurance brokerage services. BNCT-provision of boron neutron capture therapy treatment services, & Others-provision of logistic services.
19GF Score
Get the complete analysis for HKSE:08037
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08037 has been successfully added to your 
